JP2018536671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536671A5 JP2018536671A5 JP2018529006A JP2018529006A JP2018536671A5 JP 2018536671 A5 JP2018536671 A5 JP 2018536671A5 JP 2018529006 A JP2018529006 A JP 2018529006A JP 2018529006 A JP2018529006 A JP 2018529006A JP 2018536671 A5 JP2018536671 A5 JP 2018536671A5
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- azabicyclo
- octane
- amine
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-methyl-1,2,4-thiadiazol-5-yl Chemical group 0.000 claims 104
- 229910052736 halogen Inorganic materials 0.000 claims 55
- 150000002367 halogens Chemical group 0.000 claims 55
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 230000003287 optical effect Effects 0.000 claims 11
- 206010012289 Dementia Diseases 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 8
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 7
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 6
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 5
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 5
- 201000010374 Down Syndrome Diseases 0.000 claims 5
- 206010044688 Trisomy 21 Diseases 0.000 claims 5
- 206010008118 cerebral infarction Diseases 0.000 claims 5
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- GLAYEAGOETWDPL-UHFFFAOYSA-N 1H-triazolo[1,5-a]pyrazin-2-amine Chemical compound N1N(C=C2N1C=CN=C2)N GLAYEAGOETWDPL-UHFFFAOYSA-N 0.000 claims 1
- QGCRJRVFQZXCAZ-UHFFFAOYSA-N 1h-triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC=CC2=CN(N)NN21 QGCRJRVFQZXCAZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 claims 1
- WOTIUKDGJBXFLG-UHFFFAOYSA-N 3-methyl-1,2-thiazole Chemical compound CC=1C=CSN=1 WOTIUKDGJBXFLG-UHFFFAOYSA-N 0.000 claims 1
- WRTFLEDDMKKOTH-UHFFFAOYSA-N C1C=2N(C=CN1N)C=CC2 Chemical compound C1C=2N(C=CN1N)C=CC2 WRTFLEDDMKKOTH-UHFFFAOYSA-N 0.000 claims 1
- PHTMVIAGTMTVSK-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=CC=CN2N=C(N)N=C21 PHTMVIAGTMTVSK-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 C[C@](C(CC1)C2)([C@]1(*)C*2C1=N*C(C)=C1)I Chemical compound C[C@](C(CC1)C2)([C@]1(*)C*2C1=N*C(C)=C1)I 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15199260.9 | 2015-12-10 | ||
| EP15199260 | 2015-12-10 | ||
| PCT/EP2016/079816 WO2017097728A1 (en) | 2015-12-10 | 2016-12-06 | Bridged piperidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536671A JP2018536671A (ja) | 2018-12-13 |
| JP2018536671A5 true JP2018536671A5 (enExample) | 2019-12-12 |
| JP6872550B2 JP6872550B2 (ja) | 2021-05-19 |
Family
ID=54848457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529006A Active JP6872550B2 (ja) | 2015-12-10 | 2016-12-06 | 架橋されたピペリジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10562903B2 (enExample) |
| EP (1) | EP3386978B1 (enExample) |
| JP (1) | JP6872550B2 (enExample) |
| CN (1) | CN108137579B (enExample) |
| AR (1) | AR107010A1 (enExample) |
| TW (1) | TWI629278B (enExample) |
| WO (1) | WO2017097728A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20180773A1 (es) | 2015-10-02 | 2018-05-07 | Hoffmann La Roche | Anticuerpos biespecificos para pd1 y tim3 |
| CN108697709A (zh) | 2015-12-10 | 2018-10-23 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| EP3475279B1 (en) * | 2016-06-27 | 2021-07-14 | F. Hoffmann-La Roche AG | Triazolopyridines as gamma-secretase modulators |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| AR110001A1 (es) * | 2016-11-01 | 2019-02-13 | Hoffmann La Roche | Derivados heteroarilo bicíclicos |
| PT3606946T (pt) | 2017-04-03 | 2022-10-17 | Hoffmann La Roche | Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15 |
| CN116375876A (zh) | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| HUE064554T2 (hu) | 2018-09-03 | 2024-03-28 | Hoffmann La Roche | Bicikluszos heteroaril származékok |
| PL3894411T3 (pl) | 2018-12-13 | 2024-10-07 | F. Hoffmann-La Roche Ag | Pochodne 7-fenoksy-N-(3-azabicyklo[3.2.1]oktan-8-ylo)-6,7-dihydro-5H-pirolo[1,2-b][1,2,4]triazolo-2-aminy i związki pokrewne jako modulatory gamma-sekretazy do leczenia choroby Alzheimera |
| AU2019412747B8 (en) | 2018-12-27 | 2025-04-24 | F. Hoffmann-La Roche Ag | Process for the preparation exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate |
| CN117396490A (zh) * | 2021-05-14 | 2024-01-12 | Bm医药咨询有限公司 | 用于预防和治疗病毒感染的双环杂环化合物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| ES2360222T3 (es) | 2003-12-24 | 2011-06-02 | Biota Scientific Management Pty. Ltd. | Agentes policíclicos para el tratamiento de infecciones respiratorias por virus sincicial. |
| CA2624558C (en) * | 2005-10-06 | 2011-02-22 | Nippon Soda Co., Ltd. | Cross-linked cyclic amine compounds and agents for pest control |
| FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2337609B1 (en) | 2008-08-14 | 2016-08-17 | Cardiac Pacemakers, Inc. | Performance assessment and adaptation of an acoustic communication link |
| US8486967B2 (en) * | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) * | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
| WO2013101974A1 (en) | 2011-12-30 | 2013-07-04 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| BR112014018027B1 (pt) | 2012-01-26 | 2020-10-27 | Ptc Therapeutics, Inc | composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| WO2014012050A2 (en) | 2012-07-13 | 2014-01-16 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
| MX2015015691A (es) | 2013-05-14 | 2016-03-04 | Hoffmann La Roche | Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion del virus sincital respiratorio. |
| MX363456B (es) | 2013-06-25 | 2019-03-25 | Hoffmann La Roche | Compuestos para tratar atrofia muscular espinal. |
| AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
| HRP20230637T1 (hr) | 2014-05-15 | 2023-09-29 | F. Hoffmann - La Roche Ag | Postupak za proizvodnju spojeva korisnih za liječenje spinalne mišićne atrofije |
| KR102162062B1 (ko) | 2015-11-12 | 2020-10-07 | 에프. 호프만-라 로슈 아게 | 척수성 근위축증의 치료용 조성물 |
-
2016
- 2016-12-06 JP JP2018529006A patent/JP6872550B2/ja active Active
- 2016-12-06 EP EP16805853.5A patent/EP3386978B1/en active Active
- 2016-12-06 WO PCT/EP2016/079816 patent/WO2017097728A1/en not_active Ceased
- 2016-12-06 CN CN201680057010.6A patent/CN108137579B/zh active Active
- 2016-12-07 AR ARP160103753A patent/AR107010A1/es unknown
- 2016-12-09 TW TW105140951A patent/TWI629278B/zh not_active IP Right Cessation
-
2018
- 2018-06-08 US US16/004,145 patent/US10562903B2/en active Active
-
2020
- 2020-02-13 US US16/790,629 patent/US20200291034A1/en not_active Abandoned